글로벌 당뇨망막병증 시장 – 2029년까지의 산업 동향 및 예측

세계 당뇨병성 망막증 시장 분석 및 규모

최근 몇 년 동안 당뇨병성 망막증 시장은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. 당뇨병성 망막증(DR)은 전 세계적으로 시력 상실의 가장 흔한 원인입니다. 고혈당, 당뇨병 및 고혈압의 지속 기간은 시력 상실 진행에 대한 가장 임상적으로 중요한 위험 요소입니다. 혈당과 혈압을 조절하면 당뇨병성 망막증으로 인한 시력 상실을 예방하는 데 도움이 되는 것으로 입증되었습니다. 국제 당뇨병 연맹(IDF)에 따르면 2015년부터 2019년까지 전 세계 당뇨병(DM) 유병률은 약 27%였습니다. 가장 낮은 비율은 유럽(20.6%)과 동남아시아(12.5%)에서 발견되었고, 가장 높은 비율은 아프리카(33.8%), 중동 및 북아프리카(33.8%), 서태평양 지역(36.2%)에서 발견되었습니다.

• Data Bridge Market Research는 당뇨병성 망막증 시장이 2021년에 66억 달러 규모였으며 2029년까지 126억 8천만 달러에 도달할 것으로 예상하고 2022년부터 2029년까지의 예측 기간 동안 8.50%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

글로벌 당뇨망막병증 시장 정의

당뇨병은 망막의 혈관을 손상시켜 당뇨병성 망막증(DR)을 초래합니다. 당뇨병성 망막증에는 비증식성 및 증식성 또는 진행성 당뇨병성 망막증의 두 가지 유형이 있습니다. 이는 혈당 수치의 변화로 인해 눈의 빛에 민감한 구조가 비정상적으로 성장하여 발생합니다. 시야에 어두운 반점이나 떠다니는 줄, 흐릿하거나 변동하는 시력, 색각 감소 또는 시력 상실은 모두 당뇨병성 망막증의 증상입니다.

보고 범위 및 시장 세분화

당뇨병성 망막증 시장 동향

운전자

• 당뇨병 유병률 증가

당뇨병 유병률 증가는 당뇨병성 망막증 시장 성장의 주요 원동력입니다. 이와 함께 당뇨병으로 인한 실명 사례 증가는 예측 기간 동안 시장 역학에 더욱 영향을 미칠 것입니다.   

• 의료 인프라에 대한 투자 증가

당뇨망막병증 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 의료 서비스 지출이 증가하고 있다는 점인데, 이는 인프라 개선에 도움이 됩니다.

또한, 공공 및 민간 기관에서 인식을 확산하기 위한 이니셔티브가 증가함에 따라 당뇨망막병증 시장이 확대될 것입니다. 또한, 높은 가처분 소득과 유리한 상환 시나리오는 당뇨망막병증 시장이 확대되는 결과를 가져올 것입니다. 이와 함께, 노령 인구의 증가와 끊임없이 변화하는 라이프스타일은 시장의 성장률을 높일 것입니다.

기회

• 연구개발 활동의 증가       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the diabetic retinopathy market growth. Along with this, rising approvals and launches of new diabetic retinopathy drugs will further propel the 'market's growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the diabetic retinopathy market growth during the forecast period.

Restraints/Challenges Global Diabetic Retinopathy Market

On the other hand, the high cost associated with the treatment of diabetic retinopathy will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the diabetic retinopathy market. Additionally, a decline in clinical visits due to COVID-19 outbreak and post-surgical complications will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This diabetic retinopathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the diabetic retinopathy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Diabetic retinopathy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Diabetic Retinopathy Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery, while prioritizing COVID-19-related treatments, healthcare systems worldwide have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of diabetic retinopathy in recent months.

Recent Development

• In August 2020, Eyenuk had announced the U.S. Food and Drug Administration (FDA) approval for EyeArt Autonomous AI System for diabetic retinopathy screening. EyeArt is designed to help healthcare providers detect more than moderate diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopathy (vtDR) in the eyes of adults with diabetes who have never been diagnosed with more than mild diabetic retinopathy.

Global Diabetic Retinopathy Market Scope

The diabetic retinopathy market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Non-Proliferative Diabetic Retinopathy
• Proliferative Diabetic Retinopathy

Type segment for the diabetic retinopathy market is categorized into non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.

Treatment

• Medication
• Device
• Surgery
• Others

Based on treatment, the diabetic retinopathy market is segmented into medication, device, surgery and others. The medication section is further categorized into anti-vascular endothelial growth factor drug, intravitreal steroid, lipid lowering drugs and others. The device section has been sub-segmented into focal laser, vitrectomy devices, scatter laser and others.

Diagnosis

• Fluorescein Angiography
• Optical Coherence Tomography
• Others

Based on diagnosis, the diabetic retinopathy market is segmented into fluorescein angiography, optical coherence tomography and others.

Route of Administration

• Oral
• Intravitreal Injections
• Intravitreal Implants
• Others

The route of administration segment for global diabetic retinopathy market is segmented into oral, intravitreal injections, intravitreal implants and others.

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the diabetic retinopathy market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the diabetic retinopathy market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.

Diabetic Retinopathy Market Regional Analysis/Insights

The diabetic retinopathy market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Diabetic retinopathy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the diabetic retinopathy market because of the growing prevalence of diabetic retinopathy and the presence of refined healthcare expenditure in this region. Additionally, growing focus of major key players on novel technology will further propel the 'market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022 to 2029 due to the population and rising healthcare expenditure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Diabetic Retinopathy Market Share Analysis

The Diabetic retinopathy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to diabetic retinopathy market.

Some of the major players operating in the diabetic retinopathy market are:

• LEO Pharma A/S (Denmark)
• Amneal Pharmaceuticals LLC. (US)
• Glenmark Pharmaceuticals Limited (India)
• Dr. 'Reddy's Laboratories Ltd. (India)
• AstraZeneca (UK)
• 존슨앤존슨 프라이빗 리미티드(미국)
• Bausch Health Companies Inc. (캐나다)
• 엘리 릴리 앤드 컴퍼니(미국)
• AbbVie Inc.(미국)
• 애벗(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 사노피(프랑스)
• 노바티스 AG(스위스)
• Sun Pharmaceutical Industries Ltd. (인도)
• Aurobindo Pharma(인도)
• 루팡(인도)
• 알러간(아일랜드)
• 머크앤코(미국)
• IRIDEX Corporation (미국)
• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)

SKU-53232